BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

In a Tuesday press release, the FDA said the agency pushed Pfizer and BioNTech to submit the application given the ongoing Omicron surge.

Pfizer, BioNTech ask FDA to authorize two-dose COVID-19 vaccine for children under 5

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that following a request from the U.S. Food and Drug Administration (FDA) the companies have initiated a rolling submission seeking to amend the Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to include children 6 months through 4 years of age (6 months to

Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA

BioNTech and Pfizer could be about to file for authorization of their vaccine for younger kids.

Why BioNTech Stock Is Climbing Higher Today

Federal regulators are expected to be asked as soon as Tuesday to authorize Pfizer's COVID-19 vaccine for children as young as 6 months old, and the first shots could come by the end of February, according to news reports Monday night.

Pfizer may seek FDA's OK for COVID vaccine for kids under 5 as soon as Tuesday: reports

Pfizer Inc PFE and BioNTech SE BNTX are likely to submit a request for an emergency use authorization to the U.S. Food and Drug Administration on Tuesday for a COVID-19 vaccine aimed at children younger than five years. What Happened: The vaccine, made by the two companies, will be the first such available for that particular age group, according to a Washington Post report.

Pfizer Could Seek COVID-19 Vaccine Emergency Approval For Children Under 5 This Week

A Pfizer-BioNTech two-shot regimen for younger kids could be ready in the coming weeks, people briefed on the situation told the outlet on Monday.

Pfizer-BioNTech COVID-19 vaccine for kids under 5 could be ready by end of February, according to The Washington Post

Coinbase

These companies are still in their early growth stages and their numbers are likely to get even bigger in the future.

2 Stocks That Are Generating More Than 300% Sales Growth

Moderna

Are Prospects of a 4th Dose of the Pfizer-BioNTech Vaccine Dwindling?

Pfizer (PFE) and BioNTech (BNTX) announce that the first participants in a clinical study on its Omicron-specific COVID-19 vaccine candidate have been dosed.

Pfizer (PFE), BioNTech Begin Omicron-Based COVID-19 Jab Study

Novavax

The CDC is making a push for fourth shots for the immuno-compromised.

Why Coronavirus Vaccine Stocks Topped the Market Today

BioNTech (BNTX) stock is rising higher on news it and Pfizer (PFE) can test a new Covid-19 vaccine for Omicron in adults. The post BNTX Stock Alert: The Omicron Vaccine News That Has BioNTech Shooting Higher Today appeared first on InvestorPlace.

BNTX Stock Alert: The Omicron Vaccine News That Has BioNTech Shooting Higher Today

Pfizer Inc (NYSE:PFE) and BioNTech say they have signed up the first participants for a clinical trial of a vaccine tailored to target the specific Omicron variant of Covid.  The proposed vaccine will be trialed among 1,420 adults between the ages of 18-55, testing for safety, tolerability and efficacy against Omicron.

Pfizer and BioNTech set to begin trials of Omicron specific vaccine

The study will measure the safety and effectiveness of a vaccine specifically tailored to the Omicron variant in adults ages 18 to 55.

Pfizer and BioNTech have started testing an Omicron-specific COVID-19 vaccine on adults

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant. Pfizer has said that a two-dose regimen of the original vaccine may not be sufficient to protect against infection from the omicron variant.

Pfizer, BioNTech Launch Omicron-Targeted COVID-19 Vaccine Trial

COVID-19 vaccine-makers Pfizer and BioNTech announced Tuesday that the companies would test an omicron-specific vaccine candidate in healthy adults ages 18 to 55.

Pfizer, BioNTech begin omicron-specific COVID-19 vaccine study

The study will evaluate the safety and efficacy of a new shot designed to target the omicron coronavirus variant, which can evade some of the protection from existing vaccines.

Clinical Trials Begin For Pfizer And BioNTech's Omicron-Specific Covid Shot

A recent survey carried out by CNBC reported that 81% of executives worldwide say AI will play a prominent and critical role in how their businesses operate this year. Companies are phasing from the first generation of AI, which deals with pattern, text and image recognition, to decision-making AI, which helps them make timely decisions […]

Tunisian enterprise AI startup InstaDeep raises $100M from Alpha, BioNTech, Google

Pfizer Inc. PFE, -2.37% and German partner BioNTech SE BNTX, +2.36% said Tuesday they are launching a trial to evaluate an omicron-based COVID-19 vaccine in healthy adults aged 18 to 55. "While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," said Kathrin U.

Pfizer and BioNTech launch study to evaluate omicron-based COVID-19 vaccine for adults 18 to 55 years old

Pfizer CEO Albert Bourla has said the company will have the omicron vaccine ready by March.

Pfizer and BioNTech launch clinical study of Covid vaccine targeting omicron

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidate in healthy adults 18 through 55 years of age. The study will have three cohorts examining different regimens of the current Pfizer-BioNTech COVID-19 vaccine or an Omicron-based vaccine. The study will draw upon some participants from the companies' Phase

Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age

It'll be further along its way to becoming a drug development powerhouse.

Where Will BioNTech Be in 3 Years?

Ocugen, Inc.

Several factors are dragging down these vaccine stocks.

Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week

BioNTech stock, a leader in messenger RNA technology and Pfizer's Covid-19 vaccine partner, declined by almost 31% over the last month, considerably underperforming the S&P 500 which remained roughly flat over the same period. The stock also remains down by almost 55% from all-time highs seen in.

What's Happening With BioNTech Stock?

Advanced Micro Devices

Bank of America

Cigna

Chevron

Fidelity National Financial

Lloyds Banking Group

QUALCOMM

Exxon Mobil

Inflation is on fire, there are labor and supply shortages, and the Fed is hinting at multiple rate hikes. We'll look at how stocks can perform in this environment. In 2021, the market rose on low interest rates, government stimulus, and a big rebound in earnings. The breeze from these tailwinds may still blow into the New Year.

Top Stocks For 2022

BioNTech SE Sponsored ADR (BNTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

News for BioNTech SE Stock (BNTX)